Credit Suisse Group Downgrades Allena Pharmaceuticals (NASDAQ:ALNA) to Neutral

Allena Pharmaceuticals (NASDAQ:ALNA) was downgraded by equities research analysts at Credit Suisse Group from an “outperform” rating to a “neutral” rating in a research note issued to investors on Friday, Benzinga’s Daily Ratings Newsletter reports. They currently have a $4.00 target price on the stock, down from their prior target price of $7.00. Credit Suisse Group’s target price suggests a potential upside of 78.57% from the stock’s current price.

ALNA has been the subject of several other reports. ValuEngine upgraded shares of Allena Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Cowen reissued a “buy” rating on shares of Allena Pharmaceuticals in a research report on Friday, August 9th. Zacks Investment Research cut shares of Allena Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday. Roth Capital lowered their target price on Allena Pharmaceuticals from $61.00 to $31.00 in a research note on Thursday, August 8th. Finally, Wedbush reiterated a “buy” rating and issued a $26.00 price objective on shares of Allena Pharmaceuticals in a research report on Thursday, October 17th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $18.54.

Shares of ALNA traded down $3.61 during midday trading on Friday, reaching $2.24. The stock had a trading volume of 7,422,000 shares, compared to its average volume of 186,058. Allena Pharmaceuticals has a 1-year low of $2.10 and a 1-year high of $10.66. The company’s fifty day simple moving average is $4.65 and its two-hundred day simple moving average is $4.68. The company has a market cap of $138.45 million, a price-to-earnings ratio of -1.30 and a beta of 2.02. The company has a debt-to-equity ratio of 0.22, a current ratio of 6.80 and a quick ratio of 6.80.

Allena Pharmaceuticals (NASDAQ:ALNA) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.53) by ($0.01). On average, sell-side analysts forecast that Allena Pharmaceuticals will post -1.98 earnings per share for the current year.

Several hedge funds have recently made changes to their positions in ALNA. Squarepoint Ops LLC increased its position in Allena Pharmaceuticals by 3.8% in the fourth quarter. Squarepoint Ops LLC now owns 43,500 shares of the company’s stock worth $237,000 after buying an additional 1,600 shares during the last quarter. Deutsche Bank AG grew its position in shares of Allena Pharmaceuticals by 8.2% in the fourth quarter. Deutsche Bank AG now owns 28,023 shares of the company’s stock valued at $151,000 after purchasing an additional 2,118 shares in the last quarter. BlackRock Inc. grew its position in shares of Allena Pharmaceuticals by 0.8% in the fourth quarter. BlackRock Inc. now owns 581,971 shares of the company’s stock valued at $3,172,000 after purchasing an additional 4,528 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Allena Pharmaceuticals by 8.1% in the fourth quarter. Geode Capital Management LLC now owns 72,314 shares of the company’s stock valued at $394,000 after purchasing an additional 5,444 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. grew its position in shares of Allena Pharmaceuticals by 17.0% in the second quarter. Jacobs Levy Equity Management Inc. now owns 41,587 shares of the company’s stock valued at $169,000 after purchasing an additional 6,030 shares in the last quarter. Institutional investors and hedge funds own 65.41% of the company’s stock.

Allena Pharmaceuticals Company Profile

Allena Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States and internationally. The company's lead product candidate is reloxaliase, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults.

Featured Story: What is the yield curve?

Analyst Recommendations for Allena Pharmaceuticals (NASDAQ:ALNA)

Receive News & Ratings for Allena Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allena Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply